A key challenge for neuronal α-synuclein gene therapy is the development of a delivery vehicle that meets these criteria: (1) ability to cross the blood–brain barrier to target the brain after peripheral administration, (2) must be immunologically inert, and (3) allows repeated administration to be effective in the long-term given the chronic condition of PD. Here, SNCA is linked to Parkinson disease.